Stockreport

Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview [Yahoo! Finance]

Pelthos Therapeutics Inc.  (PTHS) 
PDF commercial traction for its lead product ZELSUVMI, and plans to add two additional pediatric-focused dermatology products during an investor interview hosted by Roth Cap [Read more]